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Abstract
Inflammatory response and cell death in hepatocytes are hallmarks of chronic liver
disease, and, therefore, can be effective therapeutic targets. NeurotropinH (NTP) is
a drug widely used in Japan and China to treat chronic pain. Although NTP has
been demonstrated to suppress chronic pain through the descending pain inhibitory
system, the action mechanism of NTP remains elusive. We hypothesize that NTP
functions to suppress inflammatory pathways, thereby attenuating disease
progression. In the present study, we investigated whether NTP suppresses
inflammatory signaling and cell death pathways induced by interleukin-1b (IL-1b)
and tumor necrosis factor-a (TNFa) in hepatocytes. NTP suppressed nuclear
factor-kB (NF-kB) activation induced by IL-1b and TNFa assessed by using
hepatocytes isolated from NF-kB-green fluorescent protein (GFP) reporter mice
and an NF-kB-luciferase reporter system. The expression of NF-kB target genes,
Il6, Nos2, Cxcl1, ccl5 and Cxcl2 induced by IL-1b and TNFa was suppressed after
NTP treatment. We also found that NTP suppressed the JNK phosphorylation
induced by IL-1b and TNFa. Because JNK activation contributes to hepatocyte
death, we determined that NTP treatment suppressed hepatocyte death induced by
IL-1b and TNFa in combination with actinomycin D. Taken together, our data
demonstrate that NTP attenuates IL-1b and TNFa-mediated inflammatory cytokine
expression and cell death in hepatocytes through the suppression of NF-kB and
JNK. The results from the present study suggest that NTP may become a
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preventive or therapeutic strategy for alcoholic and non-alcoholic fatty liver disease
in which NF-kB and JNK are thought to take part.
Introduction
Liver fibrosis is caused by the overproduction and deposition of collagen fibers
and persistent liver inflammation accompanied by the disabling of normal liver
regeneration that is associated with chronic viral hepatitis (e.g., hepatitis B and C),
alcoholic liver disease, non-alcoholic steatohepatitis (NASH) and autoimmune
hepatitis[1]. Liver cirrhosis is the end result of liver fibrosis, and is developed in
virtually all patients with hepatocellular carcinoma (HCC). In the United States,
liver cirrhosis is the 12th leading cause of death, with annual deaths of
approximately 30 thousand patients[2]. In Japan, the number of deaths by HCC
and liver cirrhosis (except for alcoholic liver cirrhosis) is 40 thousand annually,
surpassing the mortality of colon cancer patients[3]. Targeting the inhibition of
liver inflammation and hepatocyte death can be an effective therapy for chronic
liver diseases, including liver fibrosis. However, the discovery, development, and
clinical trials for a new drug require enormous research costs and efforts.
Therefore, the reassessment of established drugs purposed for other diseases,
which have the potential for preventive or therapeutic effects on liver disease, is
encouraged.
NeurotropinH (NTP) is a drug derived from a non-protein fraction extracted
from the inflamed skin of rabbits after the administration of vaccinia virus. NTP
has been used for more than 50 years for treatment of various chronic pain
conditions, such as low back pain, cervico-omo-brachial syndrome, post herpetic
neuralgia, hyperesthesia of subacute myelo-optic neuropathy (SMON) and other
painful conditions and the safety of NTP has already been demonstrated. In
experimental animals, Neurotropin shows anti-allodynic and anti-hyperalgesic
effects in neuropathic pain models [4, 5, 6, 7, 8, 9, 10]. In addition, the population
of patients who are the target of NTP overlaps with the population of patients
with chronic liver disease[10, 11, 12].
In chronic liver disease, such as alcoholic and non-alcoholic fatty liver disease,
the overproduction of IL-1b and TNFa is observed[13]. IL-1b binds to the IL-1
receptor whose intracellular domain interacts with MyD88 that recruits IRAK4,
IRAK1 and TRAF6[14]. Subsequently TAK1 binds to the polyubiquitin chains of
TRAF6 to be activated[15]. Activated TAK1 induces the activation of the IKK
complex and JNK1. Consequently, the transcriptional factors nuclear factor-kB
(NF-kB) and activator protein-1 (AP-1) are activated, which induce the
transcription of inflammatory genes, such as IL6 and NOS2 in hepatocytes. On the
other hand, TNFa binding to trimerized TNF receptor type I forms the complex
of the intracellular molecules, TRADD, RIP1 and TRAF2[14]. The TRAF2-linked
ubiquitin chains interact with TAK1 to activate TAK1 and its downstream IKK
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complex and JNK. In addition to the caspase-dependent cell death pathway,
TNFa-mediated JNK activation is also associated with the induction of hepatocyte
death[14]. We hypothesize that NTP suppresses the IL-1b- and TNFa-mediated
inflammatory signaling and cell death pathway through the suppression of NF-kB
and JNK activation in hepatocytes, thereby attenuating liver inflammation and
hepatocyte damage. Treatment with NTP may become a new approach for
chronic liver diseases accompanied by the chronic pain associated with musculo-
skeletal disease.
Materials and Methods
Mice, Reagents and Cells
NeurotropinH used in this study was provided by Nippon Zoki Pharmaceutical
Company Ltd., Osaka, Japan. Wild-type C57BL/6 mice were purchased from the
Jackson laboratory (Bar Harbor, ME). The study also used NF-kB-reporter green
fluorescent protein (GFP) transgenic mice that express GFP proteins under
control of the NF-kB promoter[16]. Primary hepatocytes were isolated from wild-
type C57BL/6 mice and NF-kB-reporter GFP transgenic mice by the in situ
collagenase perfusion method[17]. Cells with.90% viability were used for the
experiments. Two hours after the hepatocytes were plated, M199 medium
containing 10% fetal bovine serum (FBS) was changed to serum-free M199 media
or 1% FBS M199 media for overnight culture, and subsequently cells were treated
as described below. M199 medium was used for hepatocyte culture experiments
throughout the study. All mice received humane care according to the National
Institutes of Health recommendations outlined in their Guide for the Care and
Use of Laboratory Animals. All animal experiments were approved by the UCSD
Institutional Animal Care and Use Committee.
Measurement of NF-kB activation by the GFP reporter
After overnight serum starvation, primary hepatocytes isolated from NF-kB-
reporter GFP transgenic mice were first treated with NTP (0.01, 0.1 or 0.2 NU/
mL) for 1 hour. The cells were then treated with or without 10 ng/mL IL-1b
(R&D Systems, Minneapolis, MN) for 24 hours. The fluorescent signal intensity
of GFP of hepatocytes was then measured by fluorescent microscopy.
NF-kB luciferase assay
After changing the media to 1% FBS M199, wild type primary hepatocytes were
infected with adenoviral NF-kB-luciferase reporter at moi 10 for 16 hours[18].
The cells were first treated with NTP (0.2 or 0.4 NU/mL) for 1, 6 or 24 hours
before treatment with 2 ng/mL IL-1b or 2 ng/mL TNFa (R&D Systems,
Minneapolis, MN). Luciferase activity was measured after 8 hours of the
treatment with IL-1b or TNFa. Luciferase activity was normalized to the protein
concentration of hepatoctytes in each well.
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Quantitative real-time PCR
Primary hepatocytes were first treated with NTP (0.2 NU/mL) for one hour prior
to IL-1b or TNFa treatment, as described above. Two or six hours after treatment
with IL-1b or TNFa, Total RNA was extracted using TRIZOL (Life Technologies,
Grand Island, NY), followed by reverse transcription of total RNA to cDNA. The
cDNA subsequently underwent quantitative real-time polymerase chain reaction
(PCR) using the CFX96 real-time PCR system (Bio-Rad, Hercules, CA). PCR
primer sequences used were used: 18s rRNA forward 59-AGTCCCTGCCCTTTG-
TACACA-39. 18s rRNA reverse 59-CGATCCGAGGGCCTCACTA-39. Il6 forward
59-ACCAGAGGAAATTTTCAATAGGC-39. Il6 reverse 59-TGATGCACTTG-
CAGAAAACA-39. Nos2 forward 59-TTCTGTGCTGTCCCAGTGAG-39. Nos2
reverse 59-TGAAGAAAACCCCTTGTGCT-39. Ccl5 forward 59-CCACTTCT-
TCTCTGGGTTGG-39. Ccl5 reverse 59-GTGCCCACGTCAAGGAGTAT-39. Cxcl1
forward 59-TGCACCCAAACCGAAGTC-39. Cxcl1 reverse 59-GTCAGAAGCCAG-
CGTTCACC-39. Cxcl2 forward 59-AAAGTTTGCCTTGACCCTGAA-39. Cxcl2
reverse 59-CTCAGACAGCGAGGCACATC-39. Junb forward 59-CCTGTGTC-
TGATCCCTGACC-39. Junb reverse 59-ATCCCTATCGGGGTCTCAAG-39. Gene
expression was normalized to 18s RNA as an internal control.
Western blot
Protein extracts were electrophoresed, blotted, and then incubated with antibodies
for phospho-JNK, phospho-p65 (Ser536), caspase-3, cleaved caspase-3 (Cell
Signaling, Danvers, MA), IkBa, p65, JNK (Santa Cruz Biotechnology, Dallas, TX),
and b-actin (Sigma-Aldrich, St. Louis, MO) with appropriate secondary
horseradish peroxidase (HRP)-conjugated antibodies, and developed.
Immunofluorescence
Primary hepatocytes were pretreated with NTP (0.2 NU/mL) for 1 hour, and then
treated with 2 ng/mL IL-1b or 2 ng/mL TNFa for 15 min. Then cells were fixed
and incubated with antibody to p65 (Santa Cruz Biotechnology) and DAPI, and
imaged with fluorescent microscopy. Cells with p65-positive nucleus were
counted in 8 high power fields (x200).
Assessment of hepatocyte death
After cell attachment, hepatocytes were serum-starved for 16 hours, and first
treated with NTP (0.2 NU/mL) for one hour. The cells were then treated with
Actinomycin D (200 ng/mL; Sigma-Aldrich, St. Louis, MO) and IL-1b (2 ng/mL)
or TNFa (2 ng/mL) for an additional 16 hours [17]. Apoptosis was examined by
using the TUNEL staining kit (Roche, Indianapolis, IN). TUNEL positive cells
were counted in 10 low power fields (x100).
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Statistics
Differences between two groups were compared using the two-tailed unpaired
student t-test. Differences between multiple groups were compared using one-way
ANOVA using GraphPad Prism 4.02 (GraphPad Software, La Jolla, CA). P values
,0.05 were considered significant. All experiments were performed at least three
times and the representative data were presented.
Results
NTP suppresses NF-kB activation in hepatocytes
It has been reported that over-activation of NF-kB in hepatocytes is associated
with sustained liver inflammation [19]. Because IL-1b is a major activator of NF-
kB in hepatocytes and a potent driver of liver inflammation [20, 21], we
investigated the effect of NTP on NF-kB activity in hepatocytes. To take advantage
of the expression of GFP protein induced by activated NF-kB in NF-kB GFP
reporter mice, we used primary hepatocytes isolated from these mice [16]. IL-1b
treatment significantly increased NF-kB activity (p,0.01) in hepatocytes as
quantified by measuring GFP fluorescent signal intensity (Figure 1A,B). NTP
treatments at 0.01, 0.1 and 0.2 NU/ml one hour prior to IL-1b treatment
significantly suppressed the IL-1b-induced NF-kB activation (p,0.05)
(Figure 1A,B). We then investigated NF-kB activity by using the NF-kB luciferase
reporter system. We also assessed the effect of different durations and
concentrations of NTP pretreatment on NF-kB activation. We found that a
suppressive effect of NTP on IL-1b-mediated NF-kB activity was seen in cells with
pretreatment for one hour (p,0.05), but not for 6 or 24 hours (Figure 1C, D). In
addition, we found that 0.2 NU/mL is the most effective concentration for the
suppressive effect of NTP on NF-kB activation induced by IL-1b and TNFa
(Figure 1E, F). These results indicate that NTP at 0.2 NU/mL can suppress the
NF-kB activation induced by IL-1b and TNFa in hepatocytes. However, we found
that pretreatment with 0.4 NU/mL NTP slightly elevated the NF-kB activity
compared with the 0.2 NU/mL NTP pretreatment, suggesting that the higher
concentration of NTP may have a stimulatory effect, rather than a suppressive
effect on NF-kB activation. We also examined IkB degradation and phosphor-
ylation of NF-kBp65 to further confirm the preventive effect of NTP on NF-kB
activation. IL-1b and TNFa rapidly induced IkBa degradation (Figure 2A, B).
NTP treatment caused delayed IkBa degradation induced by IL-1b and TNFa
(Figure 2A, B), which indicates that NF-kB activation is suppressed by NTP
treatment. Phosphorylation of p65 was observed from 5 min to 15 min after
treatment with IL-1b and TNFa, whereas these phosphorylations were suppressed
by NTP pretreatment (Figure 2C, D). Nuclear translocation of p65 was also seen
in hepatocytes treated with IL-1b and TNFa (Figure 3). The NTP pretreatment
suppressed IL-1b and TNFa-induced p65 nuclear translocation (Figure 3).
Neurotropin Suppresses Inflammatory Response in Hepatocytes
PLOS ONE | DOI:10.1371/journal.pone.0114071 December 3, 2014 5 / 15
Figure 1. The suppression of interleukin-1b (IL-1b) and tumor necrosis factor-a (TNFa)-induced nuclear factor-kB (NF-kB) activation by
pretreatment of hepatocytes with Neurotropin (NTP). (A, B) Primary hepatocytes were isolated from NF-kB-GFP reporter transgenic mice. One hour
after pretreatment with NTP (0.01, 0.1 and 0.2 NU/mL), hepatocytes were treated with 10 ng/mL IL-1b for 24 hours followed by fluorescent microscopy.
Representative pictures are shown (A). Fluorescence of GFP intensity was measured (B). (C-F) Wild type (WT) primary hepatocytes were infected with
adenoviral NF-kB-luciferase reporter for 16 hours. (C, D) Subsequently, cells were pretreated with 0.2 NU/mL NTP for 1 (C), 6 or 24 hours (D) followed by
treatment with 2 ng/mL IL-1b for 8 hours and then luciferase activity was measured. (E, F) Cells were pretreated with 0.2 or 0.4 NU/mL NTP for 1 hour
followed by treatment with 2 ng/mL IL-1b (E) or TNFa (F) for 8 hours and then luciferase activity was measured. Data represent the mean¡SEM of triplicate
cultures. A representative result is shown. Similar results were obtained in three independent experiments.
doi:10.1371/journal.pone.0114071.g001
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Proinflammatory gene expression is suppressed by NTP in
hepatocytes
Because NF-kB induces an inflammatory response in the liver, we next investigated
whether NTP can suppress the induction of inflammatory mediators in hepatocytes.
IL-1b treatment induced the upregulation of mRNA expression of Il6, Nos2, Ccl5,
Cxcl1 and Cxcl2 (Figure 3A-E). The NTP treatment significantly (p,0.05) attenuated
the expression of IL-1b-induced Il6, Nos2, Ccl5, Cxcl1 and Cxcl2 in hepatocytes
(Figure 4A-E). TNFa also induced the increase of mRNA expression of Il6, Nos2,
Ccl5, Cxcl1 and Cxcl2, which was significantly suppressed (p,0.05) by NTP
pretreatment (Figure 4G-K). CXCL1 protein secreted into the supernatant was
increased by treatment with IL-1b and TNFa (Figure 4F, L). The NTP treatment
partially but significantly suppressed CXCL1 production induced by IL-1b and TNFa
(Figure 4F, L). These results demonstrated that NTP has the capacity to prevent the
inflammatory cytokine production mediated by IL-1b and TNFa in hepatocytes.
IL-1b and TNFa-mediated JNK activation is reduced by NTP
pretreatment
In addition to NF-kB, JNK is also activated by IL-1b and TNFa in hepatocytes [14].
We therefore examined the effect of NTP on JNK activation. Upon IL-1b treatment,
JNK was quickly phosphorylated in hepatocytes (Figure 5A). The IL-1b-mediated
JNK activation was reduced by NTP treatment (Figure 5A). Furthermore, the
Figure 2. Activation of the nuclear factor-kB (NF-kB) pathway induced by interleukin-1b (IL-1b) and tumor necrosis factor-a (TNFa) is suppressed
by pretreatment with Neurotropin (NTP). (A-C) Wild type (WT) primary hepatocytes were pretreated with 0.2 NU/mL NTP for 1 hour followed by the
treatment with 2 ng/mL IL-1b (A, C) or TNFa (B, D) for 5, 15, or 30 minutes. Western blots for IkB (A, B), phospho-NF-kBp65 (C, D), total p65 and b-actin are
shown. A representative result is shown. Similar results were obtained in three independent experiments.
doi:10.1371/journal.pone.0114071.g002
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upregulation of the expression of the JNK target gene Junb by IL-1b was
significantly suppressed (Figure 5B). Similarly, TNFa induced an immediate
activation of JNK in hepatocytes, and the TNFa-induced JNK phosphorylation was
suppressed by NTP pretreatment (Figure 5C). These findings indicate that NTP
pretreatment reduces not only NF-kB, but also JNK activation in hepatocytes.
NTP pretreatment suppresses IL-1b-mediated hepatocyte death
We found that NTP suppresses JNK activation that is known to promote hepatocyte
death [14]. We therefore examined the potential of NTP to prevent hepatocyte death.
Because IL-1b alone does not induce hepatocyte death[20], hepatocytes were treated
with and without sensitization by Actinomycin D during treatment with IL-1b. In
combination with Actinomycin D, IL-1b treatment caused evident hepatocyte death
after 16 hours of treatment (Figure 6A, B). Of note, NTP treatment showed a marked
reduction of IL-1b plus Actinomycin D-induced hepatocyte death as assessed by
TUNEL staining (Figure 6A, B). Cleaved caspase-3 levels were also reduced by NTP
treatment (Figure 6C). Consistently, increased JNK activation by IL-1b plus
Actinomycin D was suppressed by NTP treatment (Figure 6D). These results indicate
that NTP can prevent hepatocyte death mediated by IL-1b.
TNFa and Actinomycin D-induced hepatocyte death is prevented
by NTP pretreatment
In addition to IL-1b, we tested the preventive effect of NTP on TNFa-mediated
hepatocyte death. Similar to IL-1b, TNFa alone failed to induce hepatocyte death,
Figure 3. Neurotropin (NTP) suppresses interleukin-1b (IL-1b) and tumor necrosis factor-a (TNFa)-induced nuclear translocation of the nuclear
factor-kB (NF-kB).Wild type (WT) primary hepatocytes were pretreated with 0.2 NU/mL NTP for 1 hour followed by the treatment with 2 ng/mLTNFa or IL-
1b for 15 minutes. Immunofluorescence for NF-kBp65 is shown. Representative staining for p65 (A; Green, p65; Blue, Nucleus) and quantification (B) are
shown. Scale bar, 40 mm. Data represent the mean¡SEM of 8 high power fields (x200).
doi:10.1371/journal.pone.0114071.g003
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whereas sensitization with Actinomycin D during treatment with TNFa caused
remarkable hepatocyte death after 16 hours (Figure 7A, B). TUNEL staining
showed that NTP treatment dramatically reduced hepatocyte death caused by
treatment with TNFa plus Actinomycin D (Figure 7A, B). Cleaved caspase-3
levels were consistently suppressed by NTP treatment (Figure 7C). Additionally,
JNK activation in hepatocytes treated with TNFa plus Actinomycin D was
significantly attenuated by treatment with NTP (Figure 7D).
Discussion
Although the therapeutic effect of NTP on chronic pain that is associated with
musculo-skeletal disease has been established for decades, the effect of NTP on
liver disease has not been extensively investigated[10, 11, 12]. Chronic local
inflammation is possibly associated with chronic pain through production of
inflammatory cytokines, including IL-1b and TNFa [22, 23, 24]. It is suggested
Figure 4. Pretreatment with Neurotropin (NTP) suppresses the gene expression of inflammatory mediators by hepatocytes. (A-L) Wild type (WT)
primary hepatocytes were pretreated with 0.2 NU/mL NTP for 1 hour followed by treatment with 2 ng/mL interleukin-1b (IL-1b) (A-F) or tumor necrosis
factor-a (TNFa) (G-L) for 2 (D,E,J,K) or 6 hours (A-C, G-I). The mRNA expression of Il6, Nos2, Ccl5, Cxcl1 and Cxcl2 was measured by quantitative real time
PCR (A-E, G-K). The protein levels of CXCL1 secreted to supernatant were measured by ELISA (F, L). Data represent the mean¡SEM of triplicate cultures.
A representative result is shown. Similar results were obtained in three independent experiments.
doi:10.1371/journal.pone.0114071.g004
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that the analgesic effect of NTP might be mediated through suppression of
inflammatory cytokines and their signaling. Given the anti-inflammatory
potential of NTP, NTP may have preventive or therapeutic effects on chronic liver
inflammation, which is further associated with liver fibrosis. The present study
demonstrated that NTP suppressed both NF-kB and JNK signaling pathways
induced by IL-1b and TNFa through an unknown mechanism. Furthermore, we
confirmed that the expression of the NF-kB-target genes, Il6, Nos2, Cxcl1 and
Cxcl2, and the AP-1 target gene Junb, was also suppressed by pretreatment with
NTP. It is known that NF-kB has dual roles in hepatocytes. IL-1b and TNFa are
factors that promote alcoholic liver disease and NASH through NF-kB
Figure 5. Pretreatment with Neurotropin (NTP) suppresses interleukin-1b (IL-1b) and tumor necrosis factor-a (TNFa)-induced JNK activation in
hepatocytes. (A-C) Wild type (WT) primary hepatocytes were pretreated with 0.2 NU/mL NTP for 1 hour followed by the treatment with 2 ng/mL IL-1b (A, B)
or TNFa (C) for 15 or 30 minutes (A, C), or two hours (B). Western blots for phospho-JNK, total JNK and b-actin are shown (A, C). Representative blots are
shown. Similar results were obtained in three independent experiments. mRNA expression of Junb was measured by quantitative real time PCR. Data
represent the mean¡SEM of triplicate cultures.
doi:10.1371/journal.pone.0114071.g005
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activation[25]. Moreover, hepatocyte-specific IKKb transgenic mice, in which
hepatocyte NF-kB is over-activated, exhibited spontaneous liver inflammation
with evident liver fibrosis[19]. Thus, over-activation of NF-kB can promote liver
inflammation, and the inhibition of exacerbated NF-kB activation may attenuate
liver inflammation. On the other hand, NF-kB is associated with the induction of
anti-apoptotic genes, such as Bcl2 and Bclxl, that inhibit caspase-dependent and
JNK-dependent hepatocyte apoptosis[25]. In fact, IL-1b or TNFa alone does not
cause hepatocyte death[20, 26]. However, inhibition of NF-kB by an IkB super-
repressor or inhibition of transcription by Actinomycin D, sensitizes hepatocytes
to IL-1b and TNFa-mediated death[26]. Thus, the excessive inhibition of NF-kB
enhances liver injury. Our data demonstrated that NTP suppressed IL-1b and
TNFa-induced NF-kB activation, but did not suppress these to basal levels,
suggesting that the magnitude of the inhibitory effect caused by NTP may only
Figure 6. Interleukin-1b (IL-1b)-mediated hepatocyte death is attenuated by pretreatment with Neurotropin (NTP). (A-D) Wild type (WT) primary
hepatocytes were pretreated with 0.2 NU/mL NTP for 1 hour followed by the treatment with 2 ng/mL IL-1b with or without 200 ng/mL Actinomycin D for 16
(A, B), 8 (C) or 4 hours (D). Representative TUNEL staining (A; Red, TUNEL positivity; Blue, Nucleus.) and quantification (B) are shown. Data represent the
mean¡SEM of triplicate cultures. Western blots for caspase-3, cleaved caspase-3 (C), phospho-JNK, total JNK and b-actin are shown (D). Representative
blots are shown. Similar results were obtained in three independent experiments.
doi:10.1371/journal.pone.0114071.g006
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have preventive or therapeutic potential, but may not cause detrimental
hepatocyte damage. The inhibition of hepatocyte-derived inflammatory media-
tors, including IL-6, iNOS and chemokines, may further prevent liver
inflammation.
In contrast to the dual roles of NF-kB, the JNK pathway is associated with the
promotion of liver inflammation and hepatocyte death[14]. Persistent liver
inflammation causes sustained JNK activation that increases the generation of
reactive oxygen species and further activates JNK in the liver. Moreover, the
sustained JNK activation further activates the E3 ubiquitin ligase Itch that
ubiquitinates and degrades c-FLIP, an endogenous caspase-8 inhibitor[14]. This
results in caspase-8 activation leading to hepatocyte apoptosis[14]. In addition,
JNK activation induces the translocation of the proapoptotic proteins, BAX and
BID, to mitochondria to promote mitochondria-mediated caspase-9 activation,
thereby inducing hepatocyte death[14]. Our data show that NTP pretreatment
Figure 7. Tumor necrosis factor-a (TNFa)-mediated hepatocyte death is suppressed by pretreatment with Neurotropin (NTP). (A-D)Wild type (WT)
primary hepatocytes were pretreated with 0.2 NU/mL NTP for 1 hour followed by the treatment with 2 ng/mLTNFa with or without 200 ng/mL Actinomycin D
for 16 (A, B) 8 (C) or 4 hours (D). Representative TUNEL staining (A; Red, TUNEL staining; Blue, Nucleus) and quantification (B) are shown. Data represent
the mean¡SEM of triplicate cultures. Western blots for caspase-3, cleaved caspase-3 (C), phospho-JNK, total JNK and b-actin are shown (D).
Representative blots are shown. Similar results were obtained in three independent experiments.
doi:10.1371/journal.pone.0114071.g007
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inhibited IL-1b and TNFa-mediated JNK activation. The NTP treatment
consistently prevented IL-1b and TNFa-mediated death of hepatocytes elicited by
Actinomycin D. These results indicate that NTP can prevent liver inflammation
and hepatocyte death through suppression of JNK activation induced by IL-1b
and TNFa. Sustained hepatocyte damage also suppresses normal liver regenera-
tion, which is one of the factors for the aberrant regenerative response that
includes liver fibrosis. It is conceivable that the suppression of persistent
hepatocyte damage by NTP may restore the normal regenerative capacity of the
liver. The effect of NTP on hepatic regeneration is currently under investigation.
The results from the present study prompted us to hypothesize the preventive or
therapeutic potential of NTP on alcoholic liver disease and non-alcoholic fatty
liver disease in which IL-1b and TNFa play an important role in disease
progression. Further investigation is required to test this hypothesis.
Our data suggest that the optimal dose of NTP is important for therapeutic use.
The 0.2 NU/mL NTP dose showed an inhibitory effect on IL-1b-induced NF-kB
activation, but the inhibitory effect of NTP was weaker in conditions with the
0.4 NU/mL dosage. Thus, NTP may have an adverse effect at higher doses in
hepatocytes. Given the narrow range and presumably short half-life of NTP,
further study is required for the determination of appropriate therapeutic dose of
NTP.
Importantly, most anti-inflammatory drugs, such as non-steroidal anti-
inflammatory drugs (NSAIDs), are associated with detrimental effects on the liver.
Therefore, the development or discovery of anti-inflammatory drugs with
beneficial effects, or without any adverse effects, on the liver is highly attractive.
The present study demonstrated two valuable attributes of NTP that have been
unrecognized. First, NTP has an anti-inflammatory property. In particular, NTP
can block the activities of proinflammatory NF-kB and JNK. Second, NTP may
have a preventive or therapeutic potential for chronic liver disease. In the context
of these results, we need further investigations. First, the mechanism by which
NTP prevents NF-kB and JNK activation induced by IL-1b and TNFa needs to be
investigated. We speculate that NTP may suppress the molecule(s) shared between
IL-1b and TNFa signaling. However, it is unclear whether NTP suppresses
activation of NF-kB and JNK signaling separately or suppresses molecule(s)
shared for activation of NF-kB and JNK, such as TAK1 or K63 polyubiquitination
chains of TRAFs [15]. Second, because NTP contains various different small
molecules including nucleic acids, amino acids and sugars [10], the components
of NTP responsible for its inhibitory effect on proinflammatory signaling should
be elucidated. Third, the effect of NTP on other liver cells, such as Kupffer cells,
endothelial cells and hepatic stellate cells, should be investigated. Fourth, we need
to test the preventive or therapeutic effects of NTP on preclinical animal models
of chronic liver disease, such as alcoholic liver disease, NASH and liver fibrosis.
Thus, future investigations are required to determine whether NTP can be a new
therapeutic agent for chronic liver disease, in particular, alcoholic and non-
alcoholic fatty liver disease, in which NF-kB and JNK are thought to take part.
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